{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:24:05Z","timestamp":1787343845669,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaad.2020.03.010","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:06:42Z","timestamp":1583986002000},"page":"273-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of interleukin-6 and tumor necrosis factor-\u03b1 with mortality in hospitalized patients with cancer"],"prefix":"10.1016","volume":"84","author":[{"given":"Joseph R.","family":"Stoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toral S.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.03.010_bib1","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.jid.2017.05.010","article-title":"Incidence and triggers of Stevens-Johnson Syndrome and toxic epidermal necrolysis in a large cancer patient cohort","volume":"137","author":"Gillis","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.14052","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies","volume":"173","author":"Wu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib4","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2020.03.010_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jaad.2018.10.039","article-title":"Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions","volume":"80","author":"Mori","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor \u03b1, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.anai.2014.05.006","article-title":"Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell\u2013attracting chemokine, and interleukin-10","volume":"113","author":"Wang","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib10","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3389\/fimmu.2019.02319","article-title":"Interleukin-6 as biomarker for acute GvHD and survival after allogeneic transplant with post-transplant cyclophosphamide","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ACI.0000000000000180","article-title":"Monitoring the acute response in severe hypersensitivity reactions to drugs","volume":"15","author":"Shiohara","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2020.03.010_bib13","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"7090","key":"10.1016\/j.jaad.2020.03.010_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2020.03.010_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGF\u03b2 in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2020.03.010_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2013.01.007","article-title":"Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review","volume":"41","author":"Yu","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaad.2020.03.010_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.03.010_bib18","first-page":"1207","article-title":"Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma","volume":"19","author":"Feghali","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib19","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2020.03.010_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/0091-6749(92)90224-P","article-title":"Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals","volume":"89","author":"Lee","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2133.1994.tb03393.x","article-title":"An inflammatory eruption associated with recombinant human IL-6","volume":"130","author":"Fleming","year":"1994","journal-title":"Br J Dermtaol"},{"key":"10.1016\/j.jaad.2020.03.010_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.010_bib23","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.jaad.2020.03.010_bib24","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.03.010_bib25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ijc.31331","article-title":"Immune checkpoint blockade combined with IL-6 and TGF-beta inhibition improves the therapeutic outcome of mRNA-based immunotherapy","volume":"143","author":"Bialkowski","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaad.2020.03.010_bib26","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.12659\/MSM.907439","article-title":"Targeting interleukin-6 (IL-6) sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model","volume":"24","author":"Li","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jaad.2020.03.010_bib27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.bbmt.2011.07.001","article-title":"Tocilizumab for the treatment of steroid refractory graft-versus-host disease","volume":"17","author":"Drobyski","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2020.03.010_bib28","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.03.010_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10428194.2015.1045896","article-title":"Tocilizumab for steroid refractory acute graft-versus-host disease","volume":"57","author":"Roddy","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2020.03.010_bib30","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood.V83.6.1690.1690","article-title":"Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice","volume":"83","author":"Givon","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.03.010_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/09546630802683843","article-title":"The molecular mechanism of etanercept, an anti-tumour necrosis factor-a receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis","volume":"20","author":"Gencoglan","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.03.010_bib33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12185-011-0803-1","article-title":"Implications of TNF-\u03b1 in the pathogenesis and management of GVHD","volume":"93","author":"Levine","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jaad.2020.03.010_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib35","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/ajd.12462","article-title":"Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"58","author":"Yang","year":"2017","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.jaad.2020.03.010_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-alpha\/NF-kappaB\/Snail pathway in cancer cell migration and invasion","volume":"102","author":"Wu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2020.03.010_bib38","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/sj.bjc.6601814","article-title":"Serum levels of IL-6 and TNF-\u03b1 correlate with clinicopathological features and patient survival in patients with prostate cancer","volume":"90","author":"Michalaki","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2020.03.010_bib39","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","article-title":"Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose","volume":"25","author":"Harrison","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.03.010_bib40","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.12659\/MSM.899773","article-title":"Prognostic and therapeutic values of tumor necrosis factor-alpha in hepatocellular carcinoma","volume":"22","author":"Wang","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jaad.2020.03.010_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jdcr.2017.05.006","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) successfully treated with tumor necrosis factor-\u03b1 inhibitor","volume":"3","author":"Leman","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.03.010_bib42","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2014.04.044","article-title":"Etanercept therapy for toxic epidermal necrolysis","volume":"71","author":"Paradisi","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.03.010_bib44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2020.03.010_bib45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4103\/0019-5154.84717","article-title":"Cytokines in dermatology\u2014a basic overview","volume":"56","author":"Coondoo","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib46","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the Potential Role of Cytokines in Toxic Epidermal Necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.03.010_bib47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4049\/jimmunol.149.1.92","article-title":"Identification and induction of keratinocyte-derived IL-10","volume":"149","author":"Enk","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib48","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0002-9440(10)65667-2","article-title":"Human interleukin-10 expression in T\/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas","volume":"153","author":"Boulland","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2020.03.010_bib49","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1054\/bjoc.2000.1402","article-title":"Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma","volume":"83","author":"Boyano","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2020.03.010_bib50","first-page":"869","article-title":"TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-\u03b21 and IL-10 and tumor cells migration","volume":"24","author":"Li","year":"2014","journal-title":"Biomed Mater Eng"},{"key":"10.1016\/j.jaad.2020.03.010_bib51","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4049\/jimmunol.155.6.3112","article-title":"Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory","volume":"155","author":"Giovarelli","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2020.03.010_bib52","doi-asserted-by":"crossref","first-page":"e0139598","DOI":"10.1371\/journal.pone.0139598","article-title":"Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2020.03.010_bib53","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1200\/jco.2014.32.15_suppl.9096","article-title":"Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab","volume":"32","author":"Schindler","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030387X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222030387X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:11Z","timestamp":1759273031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222030387X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S019096222030387X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of interleukin-6 and tumor necrosis factor-\u03b1 with mortality in hospitalized patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}